The Most Common TRT Mistakes — 15 Things That Can Undermine Your Therapy's Results

Over the past several weeks, we've covered testosterone replacement therapy from nearly every angle — diagnostics, forms of administration, monitoring, side effects, and its impact on sleep, libido, muscle mass, fertility, the heart, and the prostate. This piece closes out that series and plays a different role than the rest: rather than going deep on one topic, it gathers in one place the fifteen mistakes that most often keep a therapy — despite correct qualification and a good drug — from delivering the results a patient might expect, or that create risk that could have been avoided.

One thing is worth stressing up front: TRT itself is a well-studied, legal, and, in many cases, appropriate medical intervention. The problem is almost never testosterone as a molecule — the problem is how the therapy is started, run, and monitored, and the expectations attached to it. Each of the fifteen points below points to a separate, much more detailed piece in our knowledge base and article series — treat this text as a map, not a replacement for those far deeper write-ups.

The most common mistake, made even before the first injection, is deciding based on a single, afternoon total-testosterone result. This hormone's level naturally changes over the course of the day and is highest in the morning — a reliable diagnosis requires at least two morning measurements, on separate days, ideally supplemented with LH, FSH, prolactin, SHBG, and free testosterone, to establish not just whether the hormone is low, but why. Skipping this step means some men start a lifelong therapy based on a result that could have been an artifact of time of day, poor sleep, or momentary stress rather than genuine hypogonadism.

The full checklist of tests to order before therapy — exactly what to request, in what order, and why each parameter matters — is the subject of a separate, extensive article in our knowledge base. There we also explain why the safety panel (blood count with hematocrit, PSA, lipid profile, glucose) matters just as much as confirming the hormonal deficiency itself.

The reverse of the first mistake is just as common — focusing solely on making the testosterone result 'look good' on paper, regardless of whether the patient actually feels better. Testosterone at the upper end of normal alongside persistent fatigue, low mood, or absent libido isn't a therapeutic success — it's a signal that something else needs attention: the dose may be poorly matched to the specific administration form, other causes of the symptoms may coexist (hypothyroidism, depression, sleep apnea), or the target therapeutic range simply differs from what's printed in the lab's reference table.

TRT isn't a 'set it and forget it' intervention. Monitoring doesn't end once you have a prescription — only its frequency changes depending on the phase of treatment. The first three months are the period of the most intensive checks, the following months up to a year focus on long-term safety, and once therapy stabilizes you move to an annual check-up rhythm. Patients who stop testing after the first good result lose the chance to catch a problem before it becomes serious — it's exactly regular, scheduled tests, not how you feel, that are the main tool for catching complications early.

The exact monitoring schedule — what to test in which month of therapy and why — is covered in detail in a separate article in our knowledge base, as is the interpretation of PSA results and digital rectal exams during testosterone treatment.

Testosterone stimulates the bone marrow to produce red blood cells, which in some patients leads to excessive erythrocytosis — hematocrit rising above a safe range. This is one of the few TRT side effects that climbs gradually and asymptomatically, until it reaches a level carrying real thromboembolic risk. It's a mistake to treat a slowly rising result as 'still within range, so it doesn't matter' — the trend matters in itself, regardless of whether any single result formally falls within the upper reference limit.

Buying testosterone, anastrozole, or hCG without a prescription — from the internet, a gym, or 'a friend with a connection' — strips the therapy of exactly what makes it safe: medical supervision, a controlled dose, and knowledge of what's actually in the preparation. Products from unofficial channels have documented, high variability in their actual active-substance content, and self-adding an aromatase inhibitor 'just in case' — without a measured estradiol level — just as often crashes estrogen below the needed range as it delivers any benefit.

We describe estradiol reference ranges during TRT, and when it's actually worth lowering it (and when it definitely isn't), in a separate article in our knowledge base — this is one of the most commonly misinterpreted parameters in the entire therapy.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and, with it, sperm production — in a significant proportion of men this leads to a marked decline in semen parameters, and in some to temporary infertility. This is reversible in most patients after discontinuation, but the recovery process can be long and isn't always complete, especially after years of therapy. A mistake that's hard to undo is starting TRT without first discussing whether the patient plans fatherhood in the coming years — because in that case, alternative strategies are available, such as adding hCG to maintain testicular function, or choosing a different treatment path altogether instead of classic TRT.

TRT reliably improves libido, bone mineral density, muscle mass, body composition, and partly mood in men with confirmed hypogonadism — but it isn't a cure for chronic fatigue of complex origin, for depression unrelated to a hormonal deficiency, or for motivation or relationship problems. Disappointment with therapy very often stems not from its ineffectiveness, but from expectations set too high — the patient expects a qualitative change in every area of life, while realistic, evidence-based effects have their own scope and their own pace.

Which effects appear after weeks and which only after months — and which symptoms probably won't resolve from the therapy alone — we cover week by week in a separate, detailed article, and the specific impact of low testosterone on energy levels is discussed in another piece in the series.

TRT creates a hormonal environment favorable to building muscle mass and losing fat, but it doesn't replace a training stimulus or a caloric deficit or surplus — it's a modifier of lifestyle effects, not a substitute for them. Men who start therapy and simultaneously give up regular strength training or stop paying attention to their diet, counting on the hormone alone to 'do the work', regularly end up disappointed with results — because the difference in muscle-mass gain rate between someone training on TRT and someone not training on TRT is far larger than the hormonal effect on its own, detached from a training stimulus.

What's realistically achievable in terms of muscle mass and fat loss during therapy — and what role training plays in that — is covered in two separate articles devoted respectively to building mass and losing fat on TRT.

A single worrying result or side effect — a rise in blood pressure, acne, a temporary mood dip — is often reason enough for patients to abruptly stop therapy on their own, without consulting their doctor. This is a mistake for two reasons: first, many such signals can be corrected with a dose or administration-form change rather than abandoning therapy entirely; second, abrupt discontinuation after a longer period of therapy isn't neutral — the body's own testosterone production stays suppressed for a while longer, which can lead to a period of noticeably worse wellbeing than before starting treatment.

What exactly happens to the body after stopping TRT, and how to safely plan such a decision if it's warranted, is covered in a separate article devoted entirely to that topic.

Untreated sleep apnea, obesity, and regular heavy alcohol consumption not only lower testosterone on their own — they can also reduce the effectiveness of therapy and, in the case of sleep apnea, genuinely raise the risk of complications from excessive erythrocytosis, since both factors (TRT and untreated apnea) raise hematocrit independently of each other. Starting TRT without addressing these areas in parallel is like treating a symptom while ignoring the cause — the therapy will work worse, more slowly, or with greater risk than it could if these factors were corrected alongside it.

The relationship between TRT and sleep apnea, and the impact of alcohol, training, and diet on the course of therapy, are covered in detail in two separate pieces in the series — both worth reading before starting treatment, if either factor applies to your situation.

Intramuscular or subcutaneous injections, transdermal gels, patches — each form has a different concentration profile over the day or week, a different risk of mood swings tied to peaks and troughs, a different risk of transferring the hormone to other people through skin contact, and a different level of day-to-day hassle. Choosing a form simply because 'the forum says injections are most effective' or 'gel is more convenient so it must be better' overlooks the fact that the optimal form depends on individual tolerance, lifestyle, sensitivity to concentration swings, and preferences around application frequency.

A direct comparison of injections and gel — with the real pros and cons of each form, not forum opinions — is available in a separate article in our knowledge base.

A stable blood testosterone concentration is one of the goals of well-run therapy in its own right — swings in concentration, whether from irregular gel use or injections shifted by a few days, translate directly into swings in wellbeing: days of noticeably better energy and libido interspersed with days of worse mood or fatigue, which the patient often mistakenly interprets as 'the therapy isn't working' instead of as a signal of irregular dosing. Injection frequency matters directly here — a shorter, more regular interval between doses usually gives a more stable concentration profile than rarer, larger doses.

How to choose and maintain a testosterone injection frequency to avoid this kind of swing is covered in a separate, practical article in our knowledge base.

TRT, in the vast majority of cases, is a multi-year therapy, for many patients practically lifelong — meaning a recurring cost of the drug, follow-up visits, and regular lab tests, not a one-time expense. It's a mistake to start therapy without a realistic calculation of that cost over years, which for some patients later leads to discontinuing or using therapy irregularly for purely financial reasons — and, as mistake 12 shows, that alone harms treatment effectiveness.

Approximate, current costs of therapy in Poland, and how long treatment statistically lasts, are laid out in two separate articles — worth reviewing at the decision-making stage, not only once treatment is already underway.

For a decade, concerns about a link between TRT and prostate cancer or heart disease were partly justified by uncertainty in the available data — but since then, large randomized trials, including the 2023 TRAVERSE trial covering over five thousand men, have provided much firmer answers than earlier observational data. It's a mistake to make a decision about therapy — in either direction, both quitting out of fear and dismissing genuine, still-existing risk signals — based on headlines from years ago or a forum post instead of the current state of knowledge.

The full, chronological history of these controversies — from the first FDA warnings to today's state of knowledge — as well as a separate article on TRT, prostate cancer, and PSA monitoring, are available in our knowledge base and article series.

The last, perhaps most important mistake happens even before all the ones above — skipping the question of whether, in a given clinical situation, TRT is even the best available option. In some men, especially those with secondary deficiency, moderate overweight, chronic sleep debt, or unmanaged stress, correcting these factors raises testosterone to normal values without needing to start lifelong therapy. For others who want to preserve fertility, clomiphene citrate, which stimulates the body's own hormone production instead of suppressing it, is an alternative worth considering.

A practical decision test — when it's worth trying lifestyle changes first, and when delaying TRT no longer has medical justification — as well as a direct comparison of clomiphene and TRT, are covered in two separate, extensive articles in the series. This is a question worth asking yourself, and your doctor, before, not after, therapy begins.

If you're still just considering therapy, start with our article on what TRT actually is and what tests need to be done before starting it. If you're already in treatment, compare your current check-up schedule with what we describe in the article on monitoring during TRT — that's the simplest way to check whether any of the fifteen mistakes above happens to apply to you.